CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors

Mismatch repair-deficient (dMMR) tumors show a good response toward immune checkpoint inhibitors (ICI), but developing resistance impairs patients’ outcomes. Here, we compared the therapeutic potential of an α-PD-L1 antibody with the CDK4/6 inhibitor abemaciclib in two preclinical mouse models of dM...

Descripción completa

Detalles Bibliográficos
Autores principales: Salewski, Inken, Henne, Julia, Engster, Leonie, Krone, Paula, Schneider, Bjoern, Redwanz, Caterina, Lemcke, Heiko, Henze, Larissa, Junghanss, Christian, Maletzki, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278458/
https://www.ncbi.nlm.nih.gov/pubmed/35845723
http://dx.doi.org/10.1080/2162402X.2022.2094583

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278458/
https://www.ncbi.nlm.nih.gov/pubmed/35845723
http://dx.doi.org/10.1080/2162402X.2022.2094583

Ejemplares similares